The FDA has approved Qiagen's Therascreen EGFR assay as a companion diagnostic to determine which patients are eligible to receive Boehringer Ingelheim's Gilotrif. Gilotrif, or afatinib, is a newly approved drug for patients with metastatic nonsmall-cell lung cancer who have exon 21 L858R substitution mutations and exon 19 deletions in the EGFR gene.

Related Summaries